Molecular targeting and patient individualization

Basic Clinical Radiobiology, Fourth Edition

Volumn , Issue , 2009, Pages 316-331

  Begg, Adrian C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953715983     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b15450-26     Document Type: Chapter

References (50)

1. Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY (2006). Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 38:421-30.
2. Andreassen CN, Alsner J, Overgaard M, Sorensen FB, Overgaard J (2006). Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM - a study based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 82: 577-86.
3. Begg AC, Haustermans K, Hart AA et al. (1999). The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 50: 13-23.
4. Belka C, Jendrossek V, Pruschy M, Vink S, Verheij M, Budach W (2004). Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys 58: 542-54.
5. Bentzen SM (2006). Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6: 702-13.
6. Bjork-Eriksson T, West C, Karlsson E, Mercke C (2000). Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int J Radiat Oncol Biol Phys 46: 13-19.
7. Bogaerts J, Cardoso F, Buyse M et al. (2006). Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3: 540-51.
8. Cerna D, Camphausen K, Tofilon PJ (2006). Histone deacetylation as a target for radiosensitization. Curr Top Dev Biol 73: 173-204.
9. Chang HY, Nuyten DS, Sneddon JB et al. (2005). Robustness, scalability, and integration of a woundresponse gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102:3738-43.
10. Chang-Claude J, Popanda O, Tan XL et al. (2005). Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 11: 4802-9.
11. Chi JT, Wang Z, Nuyten DS et al. (2006). Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47.
12. Choudhury A, Cuddihy A, Bristow RG (2006). Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 16: 51-8.
13. Dileto CL, Travis EL (1996). Fibroblast radiosensitivity in vitro and lung fibrosis in vivo: comparison between a fibrosis-prone and fibrosis-resistant mouse strain. Radiat Res 146: 61-7.
14. Domon B, Aebersold R (2006). Mass spectrometry and protein analysis. Science 312: 212-17.
15. Evans SM, Hahn S, Pook DR et al. (2000). Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 60: 2018-24.
16. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM (2006). MicroRNA expression and function in cancer. Trends Mol Med 12: 580-7.
17. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell 100: 57-70.
18. Helleday T, Lo J, van Gent DC, Engelward BP (2007). DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6: 923-35.
19. Hickson I, Zhao Y, Richardson CJ et al. (2004). Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64:9152-9.
20. Johansen J, Bentzen SM, Overgaard J, Overgaard M (1994). Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. Int J Radiat Biol 66:407-12.
21. Kaanders JH, Wijffels KI, Marres HA et al. (2002). Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62: 7066-74.
22. Kiltie AE, Ryan AJ, Swindell R et al. (1999). A correlation between residual radiation-induced DNA doublestrand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. Radiother Oncol 51: 55-65.
23. Krause BJ, Beck R, Souvatzoglou M, Piert M (2006). PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 50: 28-43.
24. Liu L, Gerson SL (2004). Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 5: 623-7.
25. Luo M, Kelley MR (2004). Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 24: 2127-34.
26. Magne N, Toillon RA, Bottero V et al. (2006). NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett 231: 158-68.
27. Nordsmark M, Loncaster J, Aquino-Parsons C et al. (2006). The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol 80:123-31.
28. Padhani AR, Krohn KA, Lewis JS, Alber M (2007). Imaging oxygenation of human tumours. Eur Radiol 17: 861-72.
29. Peacock J, Ashton A, Bliss J et al. (2000). Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother Oncol 55:173-8.
30. Pinkel D, Albertson DG (2005). Array comparative genomic hybridization and its applications in cancer. Nat Genet 37(Suppl): S11-7.
31. Pramana J, van den Brekel MW, van Velthuysen ML et al. (2007). Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int J Radiat Oncol Biol Phys 69:1544-52.
32. Raleigh JA, Chou SC, Calkins-Adams DP, Ballenger CA, Novotny DB, Varia MA (2000). A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin Cancer Res 6:855-62.
33. Rodemann HP, Bamberg M (1995). Cellular basis of radiation-induced fibrosis. Radiother Oncol 35:83-90.
34. Russell NS, Arlett CF, Bartelink H, Begg AC (1995). Use of fluorescence in situ hybridization to determine the relationship between chromosome aberrations and cell survival in eight human fibroblast strains. Int J Radiat Biol 68: 185-96.
35. Russell NS, Grummels A, Hart AA et al. (1998). Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer. Int J Radiat Biol 73:661-70.
36. Simon R, Sauter G (2002). Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol 30: 1365-72.
37. Sprong D, Janssen HL, Vens C, Begg AC (2006). Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys 64: 562-72.
38. Svensson JP, Stalpers LJ, Esveldt-van Lange RE et al. (2006). Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med 3: e422.
39. Taylor AM, Harnden DG, Arlett CF et al. (1975). Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 258:427-9.
40. Thompson LH, Brookman KW, Jones NJ, Allen SA, Carrano AV (1990). Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Mol Cell Biol 10: 6160-71.
41. Turesson I, Nyman J, Holmberg E, Oden A (1996). Prognostic factors for acute and late skin reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys 36: 1065-75.
42. Valerie K, Yacoub A, Hagan MP et al. (2007). Radiationinduced cell signaling: inside-out and outside-in. Mol Cancer Ther 6: 789-801
43. van den Broek GB, Wreesmann VB, van den Brekel MW, Rasch CR, Balm AJ, Rao PH (2007). Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. Clin Cancer Res 13: 4386-91.
44. Vermeulen C, Verwijs-Janssen M, Cramers P, Begg AC, Vens C (2007). Role for DNA polymerase beta in response to ionizing radiation. DNA Repair (Amst) 6:202-12.
45. Weber CN, Cerniglia GJ, Maity A, Gupta AK (2007). Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biol Ther 6: 156-9.
46. West CM, Cooper RA, Loncaster JA, Wilks DP, Bromley M (2001a). Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res 61:2907-10.
47. West CM, Davidson SE, Elyan SA et al. (2001b). Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 51: 10-5.
48. West CM, Davidson SE, Roberts SA, Hunter RD (1997). The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 76: 1184-90.
49. Xu B, Kim ST, Lim DS, Kastan MB (2002). Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 22:1049-59.
50. West CM, McKay MJ, Holscher T et al. (2005). Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys 62: 1264-73.